TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01552369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 100 days post transplantation as prophylaxis. Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 100 days post transplantation as prophylaxis. Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
Study: NCT00545779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: 150 mg orally once monthly for 6 months
Study: NCT03643237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game-based intervention
Description: The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated depression prevention program based on the model by Lewinsohn, Hoberman, Teri, \& Hautzinger, which is effective in short and long terms. The cognitive stimulation component is based on cognitive reserve and cerebral neuroplasticity. The healthy habits promotion component is based on the social learning and social cognitive theories. The App will allow participants to expand information, check progression, and receive reminders about homework

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The active control group will have access to a platform of online therapeutically inactive information related to active aging.
Study: NCT03762746

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: A custom TMS stimulator (MagStim) is used to generate repetitive biphasic magnetic pulses. Magnetic pulses are delivered with a figure-8-coil (Magnetic Coil Transducer). During the experiment, rTMS pulse intensity is adjusted to 90% of the motor threshold. Patients will be randomly assigned to receive a 1 Hz. The target area is stimulated for 10 consecutive days. Stimulation at 1 Hz was applied once a day for 10-days

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control group is receiving treatment as usual. EEG recording and psychopathological ratings are performed one day before the start and on the last day of the study
Study: NCT03381937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: speech trial
Description: speech trial during different ventilation conditions
Study: NCT00626041

Intervention type: OTHER
Group type: OTHER
Intervention: participant referral to primary care network physician
Description: blood pressure, cholesterol and hemoglobin A1c screening and management
Study: NCT03144401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: mesotac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: mesotac

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet identical to the misoprostol tablet but without the active ingredient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet identical to the misoprostol tablet but without the active ingredient
Study: NCT00094276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Asthma Communication Intervention (FACI)
Description: A caregiver/PCP communication intervention designed to facilitate communication between parents and PCPs about a child's asthma severity and recommended therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated Asthma Communication Intervention (FACI)
Description: A caregiver/PCP communication intervention designed to facilitate communication between parents and PCPs about a child's asthma severity and recommended therapy.
Study: NCT03691610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, and Rubella Virus Vaccine Live
Description: Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous, 0.5 mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, Mumps, and Rubella Virus Vaccine Live
Description: Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous, 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Virus Vaccine Live
Description: Pharmaceutical form:Suspension for injection Route of administration: Subcutaneous, 0.5 mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella Virus Vaccine Live
Description: Pharmaceutical form:Suspension for injection Route of administration: Subcutaneous, 0.5 mL
Study: NCT04413435

Intervention type: OTHER
Intervention: File Scanning
Description: The patients' epidemiological, clinical, laboratory, and radiological characteristics and treatment and outcomes data will accessed from Hospital Data Management System (HDMS) of Konya Training and Research Hospital and Public Health Management System (PHMS) of Ministry of Health.

Intervention type: OTHER
Intervention: File Scanning
Description: The patients' epidemiological, clinical, laboratory, and radiological characteristics and treatment and outcomes data will accessed from Hospital Data Management System (HDMS) of Konya Training and Research Hospital and Public Health Management System (PHMS) of Ministry of Health.
Study: NCT00635947

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isotonic solution
Description: 1.5 L- during 2-4hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water
Description: 1.5 L- during 2-4hours
Study: NCT03118219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive adjustment coping intervention
Description: see arm description
Study: NCT00635947

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: 200mL- during 2-4hours
Study: NCT03118219

Intervention type: OTHER
Group type: OTHER
Intervention: Brainteaser
Description: see arm description
Study: NCT05545618

Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA and 18F-FDG-PET/CT
Description: 18F-FDG-PET/CT imaging and comprehensive assessment of coronary plaque with CCTA within 90 days
Study: NCT03040752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine 20 Mg
Description: nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritodrine Oral Tablet
Description: Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor
Study: NCT04814459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOP-UP-PT Program
Description: Interventions provided to EG participants included; (1) the Otago Exercise Program (OEP) which is a well-established exercise program with evidence that it reduces falls among community-dwelling older adults, (2) motivational interviewing (MI) to optimize positive health behaviors, and (3) home and environmental modification recommendations aimed at safety. Participants were provided with and educated on the use of a wrist-worn activity tracker and an automated BP monitor unit. Finally, when follow up items were identified (e.g., orthostatic hypotension, community exercise classes), these referrals were made and documented.
Study: NCT02014441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Talimogene laherparepvec will be administered by intralesion injection at an initial dose of up to 4.0 mL of 10\^6 PFU/mL. The second and subsequent doses will will be up to 4.0 mL 10\^8 PFU/mL. The second dose should be administered 21 days from the initial dose. All subsequent doses should be given every 14 days.
Study: NCT03566407

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy
Description: Colonoscopy will be required for all subjects at 6 months - Visit 3.
Study: NCT02281682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
Study: NCT02227329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Prophylactic ELT will be administered at the time when the HPN is not being infused.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Lock
Description: 3 mL of 100 U/ml heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Study: NCT02281682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
Study: NCT00094276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathmobile intervention
Description: A community-based service that is specifically designed to deliver asthma screening and special consultation directly to families and children in high-risk neighborhoods.
Study: NCT02731703

Intervention type: DEVICE
Intervention: Overdenture treatment
Description: Conventional, FDA-approved prosthetics will be used in accordance with their labeling and pre-study prescribed standard treatment approach
Study: NCT02281682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: during 4 (consecutive) weeks twice daily. Prior to treatment: curettage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: during 4 (consecutive) weeks twice daily. Prior to treatment: curettage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate
Description: during 3 (consecutive) days once daily. Prior to treatment: curettage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate
Description: during 3 (consecutive) days once daily. Prior to treatment: curettage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate
Description: during 3 (consecutive) days once daily. Prior to treatment: curettage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: methylaminolevulinate photodynamic therapy
Description: methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: methylaminolevulinate photodynamic therapy
Description: methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: methylaminolevulinate photodynamic therapy
Description: methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
Study: NCT03187496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Each subject will receive midazolam on Days 1 and 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Each subject will receive caffeine on Days 1 and 12.
Study: NCT00094276

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathmobile intervention
Description: A community-based service that is specifically designed to deliver asthma screening and special consultation directly to families and children in high-risk neighborhoods.
Study: NCT03447873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue with triple therapy
Description: To continue with triple therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to DTG + 3TC
Description: Switch to dolutegravir + lamivudine once daily
Study: NCT00972504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK835726 10mg
Description: GSK835726 10mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1004723 1000mcg
Description: GSK1004723 1000mcg nasal spray solution
Study: NCT01880255

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
Study: NCT00972504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine 10mg
Description: Cetirizine 10mg active comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match actives
Study: NCT00732368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Two sprays mometasone nasal spray per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
Study: NCT00431431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tibolone
Description: 2 years treatment with tibolone (1.25 mg Org OD-14)
Study: NCT03187496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Each subject will receive rosuvastatin on Days 2 and 13.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305
Description: Each subject will receive EDP-305 on Days 5 through 15.
Study: NCT02370459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AFIX in-person consultation
Description: The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AFIX webinar consultation
Description: The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
Study: NCT00431431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raloxifen
Description: 2 years treatment with raloxifene (60 mg)
Study: NCT00003900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT01105143

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multimodal lifestyle intervention
Description: multimodal lifestyle intervention will be performed to reduce body weight

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no intervention, only follow up
Study: NCT00877513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Smoking cessation program over 8 weeks, consisting of cognitive behavioral counseling every 2 weeks along with adjunctive use of bupropion
Study: NCT01989910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegravir 400mg oral twice daily
Study: NCT01880255

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
Study: NCT02805556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: Single oral dose of BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-626529
Description: Single intravenous dose of \[13C\]BMS 626529
Study: NCT05006898

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PBO to control presbyopia symptoms
Description: Low dose PBO to control presbyopia symptoms

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PBO to control presbyopia symptoms
Description: Low dose PBO to control presbyopia symptoms

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PBO to control presbyopia symptoms
Description: Low dose PBO to control presbyopia symptoms
Study: NCT02934776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI machine
Description: The Philips Ingenia 3.0T is an MRI machine intended to be used by specialist radiologists in the hospital. It is able to acquire high quality images of wide variety of organs. For imaging the prostate, T2-weighted turbo spin-echo images are normally obtained in three orthogonal planes (axial, sagittal and coronal). This device is been clinically used in the MRI department in Belinson hospital.
Study: NCT03471767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: Dextromethorphan Immediate Release + Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion SR
Description: Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
Study: NCT01662297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be administered at a dosage prescribed by veterans' current providers for the treatment of insomnia.
Study: NCT03447873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to DRV/cobicistat + 3TC
Description: Switch to darunavir/cobicistat + lamivudine once daily
Study: NCT03537703

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Active tDCS + Auditory Training
Description: Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS + Control Condition
Description: Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The control condition will be subjects watching a silent movie for 20 min during active tDCS stimulation.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS + Auditory Training
Description: Sham tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 1 min with the current then slowly ramped down to 0 amps over the course of another minute. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
Study: NCT01662297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Veterans willing to switch from quetiapine to trazodone for the treatment of insomnia will receive up to 400mg of trazodone daily.
Study: NCT03744780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Workshop for Emotional Eating
Description: This is a one-day intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's (2016) brief emotional eating intervention, which was derived from Forman et al.'s (2013) Mind Your Health program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness.
Study: NCT01989910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenz 600mg oral at bedtime
Study: NCT02191787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seresis®
Study: NCT02467296

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary plan with controlled amount of Sodium
Description: Dietary plan with 1.5 gr vs 3 gr of Sodium
Study: NCT02191787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03154632

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Therapy
Description: Ultrasound equipment will be used, choosing a continuous mode, with a frequency of 1MHz and an intensity of 1.0 W/cm2. The technique will be applied during 6 minutes with circular movements and a speed of approximately between 2.5 and 4 centimeters per second.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Capacitive Diathermy Therapy
Description: The DCD equipment will be used choosing the musculotendinous injury FAST program which lasts 6 minutes. The applicator will move with a velocity approximately between 2.5 and 4 centimeters per second.
Study: NCT02181920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole placebo